Use of recombinant human follicle-stimulating hormone for in vitro fertilization-embryo transfer after severe systemic immunoglobulin E-mediated reaction to urofollitropin.
OBJECTIVE
To report the successful use of recombinant human FSH in a patient with a history of a severe systemic immunoglobulin E (IgE)-mediated reaction to urofollitropin.


METHODS
University hospital.


METHODS
A 38-year-old infertility patient who had experienced a whole-body rash with hives, tachycardia, fever, and other symptoms after urofollitropin administration, with confirmation of IgE-mediated sensitivity to urofollitropin by intradermal skin testing.


METHODS
In vitro fertilization-ET after the use of recombinant human FSH to stimulate ovarian follicular development.


RESULTS
Establishment of a clinical pregnancy.


CONCLUSIONS
Our case provides evidence for the involvement of nongonadotropin proteins as the direct cause of some adverse reactions from conventional urine-derived human FSH preparations.
Phipps
W R
WR
Department of Obstetrics-Gynecology, University of Rochester, New York 14642, USA.
Holden
D
D
Sheehan
R K
RK
D000328:Adult; D004342:Drug Hypersensitivity / Q000276:immunology*; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000276:immunology* / Q000627:therapeutic use* / Q000652:urine; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D011247:Pregnancy; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D007073:Immunoglobulin E; D005640:Follicle Stimulating Hormone